{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:57:55Z","timestamp":1761872275663,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014554","name":"Janssen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clml.2023.05.013","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T20:59:44Z","timestamp":1685393984000},"page":"e277-e285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse"],"prefix":"10.1016","volume":"23","author":[{"given":"Devon J.","family":"Boyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-7480","authenticated-orcid":false,"given":"Neil","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofodile","family":"Joe-Uzuegbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Gogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9390-1742","authenticated-orcid":false,"given":"Tamer N.","family":"Jarada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren R.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Elia-Pacitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel M.","family":"Ewara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2023.05.013_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.clml.2023.05.013_bib0002","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.3747\/co.26.4625","article-title":"Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada","volume":"26","author":"Le","year":"2019","journal-title":"Curr Oncol"},{"issue":"17","key":"10.1016\/j.clml.2023.05.013_bib0003","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.05.013_bib0004","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Hematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2023.05.013_bib0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2023.05.013_bib0006","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.05.013_bib0007","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, Grade 1\u20132 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol* Biol* Phys"},{"issue":"6","key":"10.1016\/j.clml.2023.05.013_bib0008","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17045","article-title":"Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"192","author":"Moccia","year":"2021","journal-title":"Br J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2023.05.013_bib0009","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.05.013_bib0010","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/j.clml.2018.12.017","article-title":"Treatment patterns and survival outcomes in patients with follicular lymphoma: a 2007 to 2015 Humedica database study","volume":"19","author":"Morrison","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2023.05.013_bib0011","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.05.013_bib0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2023.05.013_bib0013","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.05.013_bib0014","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.05.013_bib0015","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.05.013_bib0016","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","article-title":"Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems","volume":"16","author":"Perea","year":"2005","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.05.013_bib0017","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.05.013_bib0018","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.05.013_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2018-05-847558","article-title":"The FLIPI nowadays: validation and modification","volume":"132","author":"Hoster","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.05.013_bib0020","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2019-129024","article-title":"Validation of the PRIMA-prognostic index for patients treated with rituximab plus chemotherapy and refinement of prognostic parameters for patients on rituximab plus lenalidomide in the phase III relevance trial","volume":"134","author":"Julia","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.05.013_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3960\/jslrt.52.77","article-title":"Retrospective study of the utility of FLIPI\/FLIPI-2 for follicular lymphoma patients treated with R-CHOP","volume":"52","author":"Numata","year":"2012","journal-title":"J Clin Exp Hematopathol"},{"issue":"10","key":"10.1016\/j.clml.2023.05.013_bib0022","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdp053","article-title":"Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting","volume":"20","author":"van de Schans","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.05.013_bib0023","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2020003797","article-title":"Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival","volume":"5","author":"Bachy","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.05.013_bib0024","first-page":"1490","article-title":"Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study","volume":"130","author":"Launonen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.05.013_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-142000","article-title":"Evaluation of the different stratification models for POD24 prediction in patients with follicular lymphoma","volume":"136","author":"Wu","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.05.013_bib0026","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/bjs.9736","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"102","author":"Collins","year":"2015","journal-title":"J Br Surg"},{"issue":"4","key":"10.1016\/j.clml.2023.05.013_bib0027","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.05.013_bib0028","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Statis Med"},{"issue":"1","key":"10.1016\/j.clml.2023.05.013_bib0029","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for some traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"10","key":"10.1016\/j.clml.2023.05.013_bib0030","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of follicular lymphoma international prognostic index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.05.013_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2019.12.007","article-title":"Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges","volume":"471","author":"Huang","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clml.2023.05.013_bib0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","article-title":"Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","volume":"126","author":"Batlevi","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.05.013_bib0033","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.18522","article-title":"Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favorable outcome","volume":"200","author":"Munta\u00f1ola","year":"2023","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2023.05.013_bib0034","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","author":"Quan","year":"2005","journal-title":"Med Care"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:27Z","timestamp":1761871347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2152265023001829"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}